Doctors say the situation forces them to get creative in treating patients, but there’s hope that prices may fall more in the ...

Reduced monthly costs for uninsured patients still amount to around $500. That can put the drugs out of reach for many.

WeightWatchers has appointed Dr. Kim Boyd as chief medical officer and announced a new program focused on helping women ...

Walmart Inc. is giving $500,000 in grants and in-kind donations to Central Texas communities hit over the July Fourth weekend ...

The health of U.S. children has deteriorated over the past 17 years, with kids today more likely to have obesity, chronic ...

A cargo ship attacked by Yemen’s Houthi rebels sank Monday in the Red Sea, the group said, raising new concerns over safety ...

Wegovy received U.S. Food and Drug Administration (FDA) approval and was launched in June 2021, and Zepbound entered the market in December 2023 as a new contender.

"Both Wegovy and Zepbound have demonstrated clinically significant weight reduction." "For example, if a patient has fatty liver, we will choose the GLP-1 that is proven to work best for liver ...

Key Takeaways The weight loss drug Zepbound (tirzepatide) led to 50 percent more weight loss in a 72-week trial than Wegovy (semaglutide). Participants taking Zepbound lost 50 pounds (lb) on ...

The weight loss drug Zepbound (tirzepatide) led to 50 percent more weight loss in a 72-week trial than Wegovy (semaglutide). Participants taking Zepbound lost 50 pounds (lb) on average, compared ...

Nearly 32% of Zepbound users ultimately lost at least a quarter of their body weight, compared with just 16% of Wegovy users. In both groups, weight loss was about 6% lower in men than in women.